alemtuzumab

常見(jiàn)例句

Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.
阿侖單抗組有2例而抗胸腺細(xì)胞球蛋白組有3例發(fā)生排斥反應(yīng).
Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
阿侖單抗是一種針對(duì)T、B細(xì)胞的單克隆抗體。
BACKGROUND.: An increase in the incidence of autoimmune diseases has been described in patients receiing alemtuzumab.
背景：接受阿侖單抗免疫誘導(dǎo)治療治療患者的自身免疫性疾病發(fā)生率增加。
One-year cumulatie graft surial was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group.
1年累積生存率阿侖單抗組為85.;7%25;抗胸腺細(xì)胞球蛋白組為87
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿侖單抗;一種人源性抗-CD52抗體;在免疫耐受誘導(dǎo)方案中效果顯著;需要最少的免疫抑制維持藥物.
CONCLUSIONS.: In this retrospectie analysis, induction with alemtuzumab did not increase the rate of re-emergence of autoantibodies or biopsy-proen recurrence of glomerular disease.
結(jié)論：在這項(xiàng)回顧性研究分析中，阿侖單抗免疫誘導(dǎo)并不會(huì)增加自身抗體的再次出現(xiàn)率或者活組織檢查腎小球疾病的復(fù)發(fā)率。